Edwards Lifesciences (EW) announced one-year data highlighting the continued performance of its SAPIEN 3 Ultra RESILIA valve. The data were ...

Edwards Lifesciences (NYSE:EW) today announced one-year data highlighting strong performance from its Sapien 3 Ultra Resilia ...

Analyst Josh Jennings from TD Cowen maintained a Hold rating on Edwards Lifesciences (EW – Research Report) and keeping the price target at ...

Designed for patients needing a replacement valve, the company’s TAVI trial has found low rates of mortality after a year of ...

Edwards Lifesciences Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is ...

presented during the lat JPMorgan keeps an Overweight rating on Edwards Lifesciences (EW) after the company reported results from the EARLY TAVR trial, the first of its kind studying Sapien 3 in ...

Edwards Lifesciences offers a broad range of treatments for heart failures via their PASCAL repair system, EVOQUE tricuspid replacement system, and the upcoming SAPIEN 3 mitral replacement system.

Leavell Investment Management Inc. boosted its position in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 3.3% ...

GSA Capital Partners LLP bought a new position in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) in the third ...

JPMorgan keeps an Overweight rating on Edwards Lifesciences (EW) after the company reported results from the EARLY TAVR trial, the first of its kind studying Sapien 3 in asymptomatic severe aortic ...